Detected ·
Kanjin Therapeutics
——
Kanjin Therapeutics, a biotech startup developing therapeutic drugs for chronic kidney disease, received a $330,000 investment from Kyoto iCAP to establish operations in the U.S. and advance non-clinical studies.
- Website
- www.kanjin-tx.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-04-27 08:05:40 UTC
- Signal ID
- f7dc3ea5-7a58-47cb-894c-077ec9f85474
As the API returns it
{
"id": "f7dc3ea5-7a58-47cb-894c-077ec9f85474",
"created_at": "2026-04-27T08:05:40.692268Z",
"company_name": "Kanjin Therapeutics",
"company_website_url": "www.kanjin-tx.com",
"company_linkedin_url": "https://www.linkedin.com/company/kanjin-therapeutics",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Kanjin Therapeutics, a biotech startup developing therapeutic drugs for chronic kidney disease, received a $330,000 investment from Kyoto iCAP to establish operations in the U.S. and advance non-clinical studies.*"
}